Nimble Therapeutics has entered into a strategic collaboration with Incyte, a pharmaceutical company, to discover first-in-class peptide therapies across various disease areas, the company announced recently.

“This is an important collaboration for both companies to discover novel peptide-based therapeutics,” Nimble Therapeutics CEO Jigar Patel said in a statement. “We are excited to partner with Incyte, an organization with world-class drug discovery, development and commercialization capabilities, to ensure maximal patient impact across multiple disease indications.”

According to a release, the collaboration will leverage Nimble’s proprietary peptide synthesis, screening and optimization platform, along with its high chemical diversity and integrated suite of assays to enable faster discovery and optimization of promising compounds for intracellular and extracellular targets.

Financial terms were not disclosed.